DIGITAL SINGLE-USE TOTAL AND HDL CHOLESTEROL TEST

描述(改编自申请者摘要)：冠心病 (CHD)是一个重大的公共卫生问题，有超过150万的新心脏 美国每年都会发生袭击事件。超过4000万人 确诊的高脂血症和大约50%的成年人估计患有 在美国，胆固醇水平接近高水平。一年一度的 美国心脏协会估计心血管疾病的成本 协会将超过1170亿美元。Metrika实验室将发展 数字回应总胆固醇/高密度脂蛋白测试，这是一种一次性的， 基于两种物质同时测定的一次性化验 在一个小的指状血样中产生定量的数字 结果。测试设备的大小约为一张信用卡， 将结合廉价的微电子学和干试剂化学。 这一创新的测试操作非常简单，并将提供 几分钟后，结果将以数字方式显示。它可以在 或由家庭中的非专业用户使用。这项技术将 通过提供一种方便且廉价的方法来使患者受益 监测降胆固醇治疗和生活方式的有效性 变化并筛查未诊断的个体以了解两者升高的总数 胆固醇和低高密度脂蛋白--两者都是独立的风险 冠心病发生的相关因素。 建议的商业应用：不可用

DESCRIPTION (Adapted from applicant's abstract): Coronary heart disease (CHD) is a major public health problem with over 1.5 million new heart attacks each year in the United States. Over 40 million individuals have diagnosed hyperlipidemia and about 50% of adults are estimated to have borderline to high cholesterol levels in the United States. The annual cost of cardiovascular disease is estimated by the American Heart Association to be over $117 billion. Metrika Laboratories will develop the Digital Response Total/HDL Cholesterol Test which is a single-use, disposable assay based on the simultaneous measurement of both substances in a small, finger-stick blood sample to yield quantitative numerical results. The test device, which will be about the size of a credit card, will combine inexpensive microelectronics and dry reagent chemistry. This innovative test will be extremely simple to operate and will provide a digital display of results in a few minutes. It can be used at the point-of-care or by the lay user in the home. This technology will benefit patients by providing a convenient and inexpensive method to monitor the effectiveness of cholesterol- lowering treatment and lifestyle changes and to screen undiagnosed individuals for both elevated total cholesterol and low HDL-cholesterol - both of which are independent risk factors for the development of CHD. PROPOSED COMMERCIAL APPLICATION: NOT AVAILABLE